TherapeuticsMD (TXMD) PT Raised to $60 at Oppenheimer After Positive FDA Panel Vote on OCS Heart Device

April 7, 2021 7:00 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on TherapeuticsMD (NASDAQ: TXMD) to $60.00 (from $44.00) while maintaining a Outperform ...

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login